GUANGZHOU, China, Nov. 13, 2023 /PRNewswire/ -- AnchorDx, a leading diagnostics company developing ...
GUANGZHOU, China, Nov. 13, 2023 /PRNewswire/ -- AnchorDx, a leading diagnostics company developing ...
GUANGZHOU, China, Nov. 23, 2022 /PRNewswire/ -- AnchorDx, a world-leading developer of cancer early...
The company obtained a European Access Permit for in-vitro diagnostics devices (IVDD) authorized by...
GUANGZHOU, China, March 7, 2022 /PRNewswire/ -- AnchorDx, a world-leading developer of cancer scree...
GUANGZHOU, China, Dec. 9, 2021 /PRNewswire/ -- AnchorDx, a world-leading developer of cancer screen...
GUANGZHOU, China, Oct. 11, 2021 /PRNewswire/ -- The Twist Alliance Pan-Cancer Methylation Panel (Pa...
GUANGZHOU, China, Sept. 13, 2021 /PRNewswire/ -- AnchorDx, a world-leading developer of cancer scre...
GUANGZHOU, China, July 21, 2021 /PRNewswire/ -- AnchorDx, a world-leading developer of cancer scree...
GUANGZHOU, China, June 21, 2021 /PRNewswire/ -- At this year's American Society of Clinical Oncolog...
GUANGZHOU, China, April 28, 2021 /PRNewswire/ -- AnchorDx, a world-leading developer of cancer scre...
GUANGZHOU, China, April 19, 2021 /PRNewswire/ -- At this year's American Association for Cancer Res...
GUANGZHOU, China, Feb. 23, 2021 /PRNewswire/ -- AnchorDx Medical Co., Ltd. ("AnchorDx") announced t...